Compositions and methods for inhibition of the JAK pathway
View Patent ↗Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
1. A method of inhibiting an activity of a JAK kinase, comprising contacting the JAK kinase with an effective amount of N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine.
2. The method according to 1 comprising contacting the JAK kinase ex vivo.
3. The method according to 1 comprising contacting the JAK kinase in vivo.
4. The method according to claim 1 wherein contacting the JAK kinase comprises treating a disease selected from allergies, autoimmune diseases, transplant rejection, T-cell mediated autoimmune diseases, Type II inflammatory diseases, delayed Type IV hypersensitivity reactions, or hematologic malignancies.
5. The method according to claim 4 wherein the disease is rheumatoid arthritis, dry eye syndrome, uveitis, allergic conjunctivitis, glaucoma, rosacea (of the eye), multiple sclerosis (MS), amyotrophic lateral sclerosis, psoriasis, or Sjögren's syndrome.
6. A method for treating a JAK kinase-mediated disease, comprising administering to a subject an effective amount of N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine.
7. The method according to claim 6 wherein the JAK kinase mediated disease is selected from allergies, autoimmune diseases, transplant rejection, T-cell mediated autoimmune diseases, Type II inflammatory diseases, delayed Type IV hypersensitivity reactions, or hematologic malignancies.
8. The method according to claim 6 comprising administering to the subject an amount of N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine effective to treat rheumatoid arthritis.
9. The method according to claim 6 comprising administering to the subject an amount of N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine effective to treat an autoimmune disease.
10. The method according to claim 9 wherein the autoimmune disease is a T-cell mediated autoimmune disease.
11. The method according to claim 9 wherein the autoimmune disease is multiple sclerosis (MS), amyotrophic lateral sclerosis, psoriasis, or Sjögren's syndrome.
12. The method according to 6 comprising administering to a transplant recipient an amount of N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine effective to treat allograft rejection.
13. The method according to claim 12 , wherein N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine is administered in combination with, or adjunctively to, an immunosuppressant.
14. The method according to claim 6 comprising administering to the subject an amount N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine effective to treat a hypersensitivity reaction.
15. The method according to claim 6 comprising administering to the subject an amount N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine effective to treat a disease and/or disorder of the eye.
16. The method according to claim 15 wherein the disease or disorder of the eye is dry eye syndrome, uveitis, allergic conjunctivitis, glaucoma, or rosacea of the eye.
17. A method for treating asthma comprising administering to a subject an amount N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine effective to treat asthma.
18. The method according to claim 17 comprising administering N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine in combination with or adjunctively to a second therapeutic for treating asthma.
19. The method according to claim 17 comprising administering N2-(3,4,5-trimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine using a dry powder inhaler, a nebulizer, a vaporizer, or combinations thereof.